The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from GlobeNewswire (a Nasdaq OMX company)

Abiomed's Impella(R) Technology Showcased at ACC 2013

Thursday, March 07, 2013

Abiomed's Impella(R) Technology Showcased at ACC 201305:00 EST Thursday, March 07, 2013DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 15 Impella presentations in the scientific sessions at the annual American College of Cardiology (ACC) 2013 scientific meeting, scheduled from March 9 - 11, at the Moscone Convention Center in San Francisco. On the ACC show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #N6 - 233 and hands-on simulations of the Impella platform. For further information about the ACC program related to Impella and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at agenzler@abiomed.com or 978-646-1553.ABOUT ABIOMED Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com. The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13564FORWARD-LOOKING STATEMENTS This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.CONTACT: For further information please contact: Aimee Genzler Corporate Communications Manager 978-646-1553 agenzler@abiomed.com Susie Lisa Senior Director, Investor Relations, Corporate Development 978-646-1590 slisa@abiomed.com